Biobank of Samples From Patients With Infectious Diseases
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Dec 3, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The INFECTIOTEK biobank is a clinical trial designed to collect biological samples from patients with various infectious diseases. The goal is to understand these diseases better by identifying important markers that can help with diagnosis and treatment. The study will focus on patients being treated at Saint-Louis and Lariboisière Hospitals for infections such as HIV, hepatitis, bacterial infections, viral infections, and fungal infections. By gathering this information, researchers hope to learn more about how these infections affect people and how to improve patient care in the future.
To participate in this trial, you must be over 18 years old and have been diagnosed with one of the specified infectious diseases. This could include infections like HIV, hepatitis, or certain types of pneumonia, among others. If you choose to participate, you will provide samples as part of your routine medical care, and your information will help advance research in this area. It's important to note that participation is voluntary, and you can withdraw at any time if you feel uncomfortable.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient over 18 years of age
- * Diagnosed with one of the following infectious diseases :
- • Infection with HIV-1 or HIV-2, or person at risk of infection with HIV
- • Viral hepatitis (HAV, HBV, HCV, HDV, HEV)
- • Pulmonary infections: bacterial (notably Nocardia), viral (Influenza, RSV, SARS-CoV-2, Adenovirus), fungal (Aspergillus, Mucorales)
- • Urinary tract infections
- • Sexually transmitted infections (Neisseria gonorrheae, Chlamydia trachomatis, Mycoplasma genitalium, Treponema pallidum)
- • Neuromeningeal infections: (Neisseria meningitidis, Streptococcus pneumoniae), viral (HSV, VZV), fungal (Cryptococcus).
- • Infections affecting immunocompromised patients: herpes viruses (HSV, VZV, CMV, EBV), polyomavirus BK
- • Emerging pathogen X (in the event of an epidemic)
- • Signature of research consent form
- • Health coverage with social security system or state medical aid
- Exclusion Criteria:
- • Refusal to participate
- • Inability to give consent (cognitive impairment etc...)
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported